Who Generates Higher Gross Profit? Johnson & Johnson or Teva Pharmaceutical Industries Limited

Johnson & Johnson's Gross Profit Triumphs Over Teva's Decline

__timestampJohnson & JohnsonTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20145158500000011056000000
Thursday, January 1, 20154853800000011356000000
Friday, January 1, 20165020500000011859000000
Sunday, January 1, 20175109600000010825000000
Monday, January 1, 2018544900000008296000000
Tuesday, January 1, 2019545030000007536000000
Wednesday, January 1, 2020541570000007725000000
Friday, January 1, 2021553380000007594000000
Saturday, January 1, 2022553940000006973000000
Sunday, January 1, 2023586060000007646000000
Monday, January 1, 2024338790000008064000000
Loading chart...

Unleashing the power of data

A Tale of Two Giants: Johnson & Johnson vs. Teva Pharmaceutical

In the competitive world of pharmaceuticals, the battle for supremacy often boils down to financial performance. Over the past decade, Johnson & Johnson has consistently outperformed Teva Pharmaceutical Industries Limited in terms of gross profit. From 2014 to 2023, Johnson & Johnson's gross profit grew by approximately 14%, peaking at $58.6 billion in 2023. In contrast, Teva's gross profit saw a decline of around 31%, dropping to $7.6 billion in the same year.

This stark contrast highlights Johnson & Johnson's robust market strategies and diversified product portfolio, which have enabled it to maintain a steady upward trajectory. Meanwhile, Teva has faced challenges, including market competition and pricing pressures, impacting its profitability. As the pharmaceutical landscape continues to evolve, these financial insights provide a glimpse into the strategic maneuvers of these industry titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025